Answers are grounded in this paper and cite their sources.
In the present study, the antitumor effects of fenofibrate, a peroxisome proliferator‑activated receptor (PPAR)‑α agonist, on human colorectal cancer cells were investigated. Treatment of SW620 cells with fenofibrate resulted in a significant, dose‑dependent decrease in cell viability. Flow cytometric analysis showed that fenofibrate altered the cell cycle distribution in a concentration‑dependent manner: The G0/G1 fraction increased at 12.5 and 25 µM with a concomitant decrease in the S fraction, whereas at 50 µM, the G0/G1 fraction was depleted and both the S and G2/M fractions increased, indicating perturbation of cell cycle progression rather than uniform arrest in a single phase. Annexin V/propidium iodide staining revealed only marginal changes in the apoptotic and necrotic populations, and the combined proportion of early apoptotic, late apoptotic and necrotic cells remained <4% at all tested concentrations, consistent with limited overt cell death. Western blot analysis performed in three independent experiments revealed a concentration‑dependent decrease in the expression of the cell cycle regulators Cyclin D1 and Cyclin B1, which was statistically significant at 50 µM. Papanicolaou staining, performed in four independent experiments, revealed a significant, dose‑dependent decrease in the mitotic index. These results suggest that fenofibrate suppresses SW620 cell proliferation predominantly through cytostatic effects and concentration‑dependent alterations in cell cycle distribution, rather than through marked apoptosis induction. Although this study suggests that fenofibrate could be a potential therapeutic strategy for cancer treatment, further investigation is required to elucidate its underlying molecular mechanisms.
No takes yet. Share an insight, caveat, or question.
Morinishi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: